A preclinical study showed that treatment of glioblastoma stem cell-engrafted mice, with allogeneic NK cells in combination with inhibitors of integrin or TGF-β signaling or with TGFBR2 gene-edited allogeneic NK cells, prevented GSC-induced NK cell dysfunction and tumor growth. This evidence concerns the gene TGFB1 and glioblastoma.